Supernus receives Paragraph IV ANDA filings for Qelbree; patents expire 2029-2035

SUPERNUS PHARMACEUTICALS, INC.

Received Paragraph IV notice letters for ANDA of viloxazine ER capsules 100, 150, 200 mg.
Six Orange Book patents listed; three expire Sept 2029, two Feb 2033, one April 2035.
Company intends to vigorously enforce its Qelbree intellectual property rights.
Currently reviewing details of the ANDA filings from third parties.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.